Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes.

Autor:	Clase CM; Department of Medicine and Clinical Epidemiology, McMaster University, Hamilton, Ontario, Canada. Electronic address: clase@mcmaster.ca., Barzilay J; Kaiser Permanente of Georgia, Atlanta, Georgia, USA., Gao P; Population Heart Research Institute, Hamilton, Ontario, Canada., Smyth A; Department of Nephrology, Galway University Hospitals, Gaillimh, Connacht, Ireland., Schmieder RE; Department of Medicine, University Hospital Erlangen, Erlangen, Bavaria, Germany., Tobe S; Department of Medicine, Sunnybrook HSC, Toronto, Ontario, Canada., Teo KK; Department of Medicine and Clinical Epidemiology, McMaster University, Hamilton, Ontario, Canada; Population Heart Research Institute, Hamilton, Ontario, Canada., Yusuf S; Department of Medicine and Clinical Epidemiology, McMaster University, Hamilton, Ontario, Canada; Population Heart Research Institute, Hamilton, Ontario, Canada., Mann JF; Departments of Nephrology and Hypertension, Friedrich Alexander University, Erlangen, Bavaria, Germany.
Jazyk:	angličtina
Zdroj:	Kidney international [Kidney Int] 2017 Mar; Vol. 91 (3), pp. 683-690. Date of Electronic Publication: 2016 Dec 04.
DOI:	10.1016/j.kint.2016.09.038
Abstrakt:	Initiation of blockade of the renin-angiotensin system may cause an acute decrease in glomerular filtration rate (GFR): the prognostic significance of this is unknown. We did a post hoc analysis of patients with, or at risk for, vascular disease, in two randomized controlled trials: Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) and the Telmisartan Randomized AssessmeNt Study in ACE iNtolerant participants with cardiovascular Disease (TRANSCEND), whose median follow-up was 56 months. In 9340 patients new to renin-angiotensin system blockade, who were then randomized to renin-angiotensin system blockade, a fall in GFR of 15% or more at 2 weeks after starting renin-angiotensin system blockade was seen in 1480 participants (16%), with persistence at 8 weeks in 700 (7%). Both acute increases and decreases in GFR after initiation of renin-angiotensin system blockade were associated with tendencies, mostly not statistically significant, to increased risk of cardiovascular outcomes, which occurred in 1280 participants, and of microalbuminuria, which occurred in 864. Analyses of creatinine-based outcomes were suggestive of regression to the mean. In more than 3000 patients randomized in TRANSCEND to telmisartan or placebo, there was no interaction between acute change in GFR and renal or cardiovascular benefit from telmisartan. Thus, both increases and decreases in GFR on initiation of renin-angiotensin system blockade are common, and may be weakly associated with increased risk of cardiovascular and renal outcomes. Changes do not predict increased benefit from therapy. (Copyright © 2016 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu